Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Invitae, a medical genetic testing company, has filed for Chapter 11 bankruptcy and intends to continue the case without disrupting operations using cash on hand and while seeking to sell its business ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min More than 4 million people have ...

Shares of Invitae are trading for less than a nickel apiece after a report surfaced earlier this week claiming the genetic testing company is on the verge of filing for bankruptcy. The report came ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Feb 13 (Reuters) - Softbank-backed (9434.T), opens new tab genetic test maker Invitae (NVTA.PK), opens new tab said on Tuesday it has filed for voluntary Chapter 11 protection in a U.S. bankruptcy ...

– Company achieves over 1 million ClinVar submissions to advance science and patient care – Unlike most companies, Invitae offers patients a choice on whether or not to allow access to their ...

— The transaction contributes to Invitae's cash runway and includes a strategic supply partnership to support the growth of Invitae Personalized Cancer Monitoring™ (PCM) services — SAN FRANCISCO, Dec.